BMO Capital Markets adjusted its outlook on American Tower Corporation (NYSE:AMT), reducing the price target to $210 from $230, while continuing to endorse the stock with an Outperform rating. The ...
Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback